Determination of sumatriptan in human plasma using liquid chromatography-mass spectrometry for pharmacokinetic study in healthy Korean volunteers.
10.12793/tcp.2017.25.2.106
- Author:
Seungil CHO
1
;
Moonyoung JEGAL
;
Boram OHK
;
Bo Kyung KIM
;
Mi Ri GWON
;
Woo Youl KANG
;
Sook Jin SEONG
;
Hyun Ju KIM
;
Hae Won LEE
;
Young Ran YOON
Author Information
1. Department of Biomedical Science, BK21 Plus KNU Bio-Medical Convergence Program for Creative Talent and Clinical Trial Center, Kyungpook National University Graduate School and Hospital, Daegu 41944, Korea. chosi1@gmail.com, yry@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Sumatriptan;
HPLC-MS/MS;
Pharmacokinetic study;
Human plasma;
Method validation
- MeSH:
Area Under Curve;
Body Weight;
Calibration;
Chromatography, Liquid;
Female;
Healthy Volunteers;
Humans*;
Male;
Methods;
Plasma*;
Quality Control;
Sensitivity and Specificity;
Spectrum Analysis*;
Sumatriptan*;
Tandem Mass Spectrometry;
Volunteers*
- From:Translational and Clinical Pharmacology
2017;25(2):106-111
- CountryRepublic of Korea
- Language:English
-
Abstract:
This study describes the development of an analytical method to determine sumatriptan levels in human plasma using high performance liquid chromatography (HPLC) coupled with triple quadrupole tandem mass spectrometry (MS/MS) and its application to a pharmacokinetic study in healthy Korean volunteers. A single 50 mg dose of sumatriptan was orally administered to twelve healthy volunteers (nine women and three men). The HPLC-MS/MS analytical method was validated with respect to its specificity, linearity, sensitivity, accuracy, precision, recovery, and stability. The calibration curve was linear over a concentration range of 0.3–100 ng/mL (r > 0.999). The lower limit of quantitation for sumatriptan in plasma was 0.3 ng/mL. The accuracy and precision of the analytical method were acceptable within 15% at all quality control levels. We compared plasma concentration-time curves as well as pharmacokinetic parameters such as the area under the curve (AUC) and maximum plasma concentration (C(max)). Both the mean AUC and C(max) of sumatriptan were 1.56 times higher in women than in men. These differences could be largely explained by the difference in body weight (44%) between women and men. The outcomes may provide insights into developing appropriate individualized treatment strategies.
